Eli Lilly

Deutsche Bank cuts Novo Nordisk to Sell after 70% slide

Deutsche Bank became the first major bank to issue an outright Sell rating on Novo Nordisk since the Danish drugmaker's shares collapsed roughly 70% from their 2025 peak, cutting its price target by 9% to 265 Danish crowns from 290…

FDA clears Roche, Eli Lilly blood test for Alzheimer’s

The U.S. Food and Drug Administration has cleared a blood test developed by Roche in collaboration with Eli Lilly that can help detect signs of Alzheimer's disease through a simple blood draw, potentially transforming how the condition is diagnosed across…

Novo Nordisk shares slide despite earnings beat on Wegovy pill miss

Novo Nordisk shares fell more than 6% on Tuesday after the Danish drugmaker released its second-quarter 2026 earnings a day ahead of schedule, with investors seizing on a narrow miss in oral Wegovy sales and a cautious full-year outlook despite…

Novo Nordisk CEO pledges bolt-on deals after pipeline setbacks sink shares

Novo Nordisk CEO Mike Doustdar on Wednesday pledged to accelerate research and pursue bolt-on acquisitions to rebuild the Danish drugmaker's pipeline, as investors expressed frustration over a string of clinical trial setbacks that have overshadowed an upgraded 2026 outlook.

Novo Nordisk beats Q2 forecasts, raises 2026 outlook

Novo Nordisk, the Danish maker of weight-loss drug Wegovy, reported second-quarter adjusted operating profit that exceeded analyst expectations on Tuesday and raised its full-year 2026 outlook for the second time this year, citing stronger-than-expected sales of its GLP-1 drugs for…

Lilly plans Q1 2027 FDA filing for obesity drug retatrutide

Eli Lilly announced Thursday that it will submit a Biologics License Application for its next-generation obesity drug retatrutide to the U.S. Food and Drug Administration in the first quarter of 2027, after reporting positive results from two additional Phase 3…

Novo Nordisk demands price cuts from suppliers amid margin squeeze

Novo Nordisk has written to its suppliers requesting price reductions as the Danish pharmaceutical giant grapples with mounting cost pressures in a rapidly changing weight-loss drug market, according to a report by MedWatch on Wednesday. The correspondence gave suppliers only…

Eli Lilly says Trump pricing policy will delay obesity drug launches in Europe

Eli Lilly said on Tuesday that the Trump administration's most-favored-nation pricing policy will affect its plans to launch its weight-loss pill in Europe and Britain, with the rollout now expected in the second half of 2026 or early 2027. The…